GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Biotech Acquisition Co (NAS:BIOT) » Definitions » Net Income

Biotech Acquisition Co (Biotech Acquisition Co) Net Income : $8.04 Mil (TTM As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Biotech Acquisition Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Biotech Acquisition Co's Net Income for the three months ended in Sep. 2022 was $1.26 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2022 was $8.04 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Biotech Acquisition Co's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was $0.04.


Biotech Acquisition Co Net Income Historical Data

The historical data trend for Biotech Acquisition Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotech Acquisition Co Net Income Chart

Biotech Acquisition Co Annual Data
Trend Dec20 Dec21
Net Income
- -6.87

Biotech Acquisition Co Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Net Income Get a 7-Day Free Trial Premium Member Only 2.94 -7.29 4.68 9.38 1.26

Biotech Acquisition Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Biotech Acquisition Co's Net Income for the fiscal year that ended in Dec. 2021 is calculated as

Net Income(A: Dec. 2021 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-6.865+0+0+0
=-6.87

Biotech Acquisition Co's Net Income for the quarter that ended in Sep. 2022 is calculated as

Net Income(Q: Sep. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=1.261+0+0+0
=1.26

Net Income for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biotech Acquisition Co  (NAS:BIOT) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Biotech Acquisition Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Biotech Acquisition Co Net Income Related Terms

Thank you for viewing the detailed overview of Biotech Acquisition Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotech Acquisition Co (Biotech Acquisition Co) Business Description

Traded in Other Exchanges
N/A
Address
545 West 25th Street, 20th Floor, New York, NY, USA, 10001
Website
Biotech Acquisition Co is a blank check company.
Executives
Albert F Hummel director, officer: Chief Investment Officer PO BOX 3407, RANCHO SANTA FE CA 92067
Biotech Sponsor Llc 10 percent owner 545 W. 25TH ST., 20TH FLOOR, NEW YORK NY 10001
Bruno Montanari director 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Ivan Jarry officer: Chief Operating Officer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001
Paul Bernard director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Aaron Kim director 545 WEST 25TH STREET 20TH FL, NEW YORK NY 10001
Michael Schleifer director, 10 percent owner, officer: Chief Executive Officer 545 WEST 25TH STREET 20TH FLOOR, NEW YORK NY 10001
Thomas Fratacci officer: CFO & Treasurer 545 WEST 25TH STREET, 20TH FLOOR, NEW YORK NY 10001

Biotech Acquisition Co (Biotech Acquisition Co) Headlines

From GuruFocus

Biotech Acquisition Company Announces Liquidation

By GlobeNewswire GlobeNewswire 02-02-2023